- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S7896
|
In vitro |
DMSO
: 100 mg/mL
(191.68 mM)
Water : 100 mg/mL Ethanol : 46 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 521.69 | Formula | C26H44NNaO6S |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 35807-85-3 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC(CCC(=O)NCCS(=O)(=O)[O-])C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C.[Na+] | ||
| In vitro |
In vitro, Tauroursodeoxycholate shows protective and reversing effects on 17βEG-induced impairment of the cVA-of-CLF. In Mz-ChA-1 cholangiocarcinoma cells, Tauroursodeoxycholate inhibits cell growth via Ca2+-, PKC-, and MAPK-dependent pathways. In isolated rat hepatocytes, Tauroursodeoxycholate inhibits bile acid-Induced Apoptosis via a β1-integrin-mediated formation of cAMP.
|
|---|---|
| In vivo |
In phalloidin-induced cholestasis rats, Tauroursodeoxycholate (360 μmol/kg, i.v.) significantly suppresses the decrease in bile flow and increases in serum alkaline phosphatase, leucine aminopeptidase and glutamic pyruvic transaminase activities, cholesterol, phospholipid and bile acid concentrations.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05753852 | Recruiting | Amyotrophic Lateral Sclerosis |
Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital Tours|KU Leuven|UMC Utrecht|University of Dublin Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanità|Motor Neurone Disease Association |
October 25 2021 | Phase 3 |
| NCT04114292 | Unknown status | Ulcerative Colitis |
Washington University School of Medicine|Crohn''s and Colitis Foundation |
January 17 2019 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Question 1:
What’s the difference between it (S7896) and TUDCA (S3654)?
Answer:
It is the sodium salt of TUDCA.